Lecicarbon Felnőtt (Sodium Hydrogen Carbonate, Sodium Dihydrogen Phosphate)

Sodium hydrogen carbonate dissociates to release bicarbonate ions, which act as a base and combine with hydrogen ions in the rectal lumen. This reaction raises the local pH, creating a less acidic environment. The accompanying sodium dihydrogen phosphate supplies phosphate ions that further support buffering capacity.

The appropriate dose of Lecicarbon Felnőtt is determined by the prescribing healthcare professional based on the specific clinical situation, patient characteristics, and the intended procedure. Dosage instructions are provided on the product label and should be followed exactly as directed by the prescriber.

Safety data for Lecicarbon Felnőtt in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should evaluate the individual situation and discuss potential risks with the patient.

To request Lecicarbon Felnőtt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Lecicarbon Felnőtt combines sodium hydrogen carbonate and sodium dihydrogen phosphate, offering dual buffering action that can achieve a more stable pH than single‑component agents. This may provide more consistent pH control during procedures, though the choice of product depends on clinical preference, formulation availability and specific procedural requirements.

Lecicarbon Felnőtt should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. No refrigeration is required.

The product is administered rectally, typically as an enema. The prescribed volume is introduced into the rectum using the supplied applicator or a compatible device, following the instructions provided by the healthcare professional to ensure proper distribution and absorption.

The most serious risks include severe allergic reactions (anaphylaxis), significant electrolyte disturbances such as hypernatremia, and metabolic alkalosis from excessive absorption of bicarbonate. Patients should be monitored for signs of these conditions, especially if they have underlying renal or cardiac disease.

Lecicarbon Felnőtt should be avoided in patients with known hypersensitivity to sodium hydrogen carbonate, sodium dihydrogen phosphate, or any excipients in the formulation. It is also contraindicated in individuals with severe electrolyte imbalances, uncontrolled metabolic alkalosis, or those receiving other systemic alkalinizing agents without medical supervision.